These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 6398233

  • 1. [Bone marrow regulatory factors (BMRF) and the transplanting of bone marrow: a model of morphostasis and immunity].
    Pierpaoli W, Maestroni GJ.
    Fiziol Cheloveka; 1984; 10(2):234-41. PubMed ID: 6398233
    [No Abstract] [Full Text] [Related]

  • 2. Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments.
    Wood ML, Gozzo JJ, Monaco AP.
    Transplant Proc; 1972 Dec; 4(4):523-9. PubMed ID: 4405146
    [No Abstract] [Full Text] [Related]

  • 3. Active enhancement of tissue allografts with antilymphocyte serum and bone marrow.
    Monaco AP, Liegeois A, Wood ML, Clark AW.
    Adv Nephrol Necker Hosp; 1975 Dec; 5():135-72. PubMed ID: 242206
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Soluble H-2 antigens: effect on graft-versus-host reaction and factors influencing its effect on host-versus-skin-graft reaction.
    Halle-Pannenko O, Martyre MC, Mathé G.
    Transplant Proc; 1972 Dec; 4(4):517-21. PubMed ID: 4405145
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Protection against secondary syndrome by facilitating immune sera.
    Voisin JE, Kinsky RG, Voisin GA.
    Ann Immunol (Paris); 1973 Feb; 124(1):75-85. PubMed ID: 4146716
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanism of augmented graft survival in mice after ALS and bone marrow infusion.
    Wood ML, Heppner G, Gozzo JJ, Monaco AP.
    Transplant Proc; 1973 Mar; 5(1):691-6. PubMed ID: 4572128
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Immunological studies in experimental bone marrow transplantation].
    Onoe K.
    Gan No Rinsho; 1989 May; Spec No():279-86. PubMed ID: 2689667
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing.
    Wood ML, Monaco AP, Gozzo JJ, Liegeois A.
    Transplant Proc; 1971 Mar; 3(1):676-9. PubMed ID: 4398508
    [No Abstract] [Full Text] [Related]

  • 19. Two distinct types of late onset graft-versus-host disease after bone marrow transplantation in lethally irradiated mice.
    Heidt PJ, Wagemaker G, Knaan-Shanzer S, van Bekkum DW.
    Transplantation; 1981 Sep; 32(3):263-4. PubMed ID: 7025379
    [No Abstract] [Full Text] [Related]

  • 20. [Increased efficacy of allogenic bone marrow transplantation].
    Fedotenkov AG, Danilova LA, Ignasheva LP.
    Biull Eksp Biol Med; 1982 Aug; 94(8):104-8. PubMed ID: 6751429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.